Biological basis for the use of autologous bone marrow stromal cells in the treatment of congenital pseudarthrosis of the tibia

Bone

Volumn 46, Issue 3, 2010, Pages 780-788

  Granchi, Donatella ^a   Devescovi, Valentina ^a   Baglìo, Serena Rubina ^a   Leonardi, Elisa ^a   Donzelli, Onofrio ^a   Magnani, Marina ^a   Stilli, Stefano ^a   Giunti, Armando ^a   Baldini, Nicola ^a  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

Author keywords

Bone; Bone marrow stromal cells; Congenital pseudarthrosis of the tibia; Type I neurofibromatosis

Indexed keywords

ALKALINE PHOSPHATASE; BONE SIALOPROTEIN; COLLAGEN TYPE 1; COLLAGEN TYPE 1 ALPHA 1 CHAIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; OSTEOCALCIN; OSTEONECTIN; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; BONE DEVELOPMENT; BONE MARROW; CELL DIFFERENTIATION; CHILD; CLINICAL ARTICLE; CONGENITAL PSEUDARTHROSIS; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; ILIAC CREST; INFANT; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; NEUROFIBROMATOSIS; NUCLEOTIDE SEQUENCE; OSTEOBLAST; TIBIA; TISSUE REGENERATION; AUTOTRANSPLANTATION; BONE MARROW TRANSPLANTATION; CELL CULTURE; COCULTURE; COMPARATIVE STUDY; PATHOLOGY; PRESCHOOL CHILD; PSEUDARTHROSIS; RADIOGRAPHY; STROMA CELL; TRANSPLANTATION; TREATMENT OUTCOME;

ADOLESCENT; BONE MARROW; BONE MARROW TRANSPLANTATION; CELLS, CULTURED; CHILD; CHILD, PRESCHOOL; COCULTURE TECHNIQUES; FEMALE; HUMANS; INFANT; MALE; PSEUDARTHROSIS; STROMAL CELLS; TIBIA; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 77649189822     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2009.10.044     Document Type: Article

References (34)

1. Vander Have K.L., Hensinger R.N., Caird M., Johnston C., Farley F.A. Congenital pseudarthrosis of the tibia. J Am Acad Orthop Surg 2008, 16:228-236.
2. Vitale M.G., Guha A., Skaggs D.L. Orthopaedic manifestations of neurofibromatosis in children. An update. Clin Orthop Relat Res 2002, 401:107-118.
3. Crawford A.H., Schorry E.K. Neurofibromatosis update. J Pediatr Orthop 2006, 26:413-423.
4. Tseng S.S., Lee M.A., Reddi A.H. Nonunions and the potential of stem cells in fracture-healing. J Bone Joint Surg Am 2008, 90(S1):92-98.
5. Bianco P., Riminucci M., Gronthos S., Robey P.G. Bone marrow stromal stem cells: nature, biology, and potential applications. Stem Cells 2001, 19:180-192.
6. Ciapetti G., Ambrosio L., Marletta G., Baldini N., Giunti A. Human bone marrow stromal cells: In vitro expansion and differentiation for bone engineering. Biomaterials 2006, 27:6150-6160.
7. Brooke G., Cook M., Blair C., Han R., Heazlewood C., Jones B., et al. Therapeutic applications of mesenchymal stromal cells. Semin Cell Dev Biol 2007, 18:846-858.
8. Novicoff W.M., Manaswi A., Hogan M.V., Brubaker S.M., Mihalko W.M., Saleh K.J. Critical analysis of the evidence for current technologies in bone-healing and repair. J. Bone Joint Surg Am 2008, 90(S1):85-91.
9. Hernigou P., Mathieu G., Poignard A., Manicom O., Beaujean F., Rouard H. Percutaneous autologous bone-marrow grafting for nonunions. Surgical technique. J Bone Joint Surg Am 2006, 88(S1):322-327.
10. Garg N.K., Gaur S. Percutaneous autogenous bone-marrow grafting in congenital tibial pseudarthrosis. J Bone Joint Surg Br 1995, 77:830-831.
11. Kitoh H., Kitakoji T., Tsuchiya H., Mitsuyama H., Nakamura H., Katoh M., et al. Transplantation of marrow-derived mesenchymal stem cells and platelet-rich plasma during distraction osteogenesis-a preliminary result of three cases. Bone 2004, 35:892-898.
12. Cho T.J., Choi I.H., Lee K.S., Lee S.M., Chung C.Y., Yoo W.J., et al. Proximal tibial lengthening by distraction osteogenesis in congenital pseudarthrosis of the tibia. J Pediatr Orthop 2007, 27:915-920.
13. Leskelä HV, Kuorilehto T, Risteli J, Koivunen J, Nissinen M, Peltonen S, et al. Congenital pseudarthrosis of neurofibromatosis type 1: Impaired osteoblast differentiation and function and altered NF1 gene expression. Bone 2009;44:243-50.
14. Coelho M.J., Fernandes M.H. Human bone cell cultures in biocompatibility testing. Part II: effect of ascorbic acid, beta-glycerophosphate and dexamethasone on osteoblastic differentiation. Biomaterials 2000, 21:1095-1102.
15. Granchi D, Ochoa G, Leonardi E, Devescovi V, Baglìo SR, Osaba L, et al. Gene expression patterns related to osteogenic differentiation of bone marrow-derived mesenchymal stem cells during ex vivo expansion. Tissue Eng Part C Methods. 2009 Aug 17. [Epub ahead of print].
16. Neurofibromatosis. NIH Consens Statement Online 1987 Jul 13-15;6(12):1-19.[]. http://consensus.nih.gov/1987/1987Neurofibramatosis064html.htm.
17. Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8:315-317.
18. Granchi D., Baglìo S.R., Amato I., Giunti A., Baldini N. Paracrine inhibition of osteoblast differentiation induced by neuroblastoma cells. Int J Cancer 2008, 123:1526-1535.
19. Mouritzen P., Noerholm M., Nielsen P.S., Jacobsen N., Lomholt C., Pfundheller H.M., et al. ProbeLibrary: a new method for faster design and execution of quantitative real-time PCR. Nat Methods 2005, 4:313-316.
20. Hernigou P., Beaujean F. Bone marrow in patients with pseudarthrosis. A study of progenitor cells by in vitro cloning. Rev Chir Orthop Reparatrice Appar Mot 1997, 83:33-40.
21. Seebach C., Henrich D., Tewksbury R., Wilhelm K., Marzi I. Number and proliferative capacity of human mesenchymal stem cells are modulated positively in multiple trauma patients and negatively in atrophic nonunions. Calcif Tissue Int 2007, 80:294-300.
22. Hofmann A., Ritz U., Hessmann M.H., Schmid C., Tresch A., Rompe J.D., et al. Cell viability, osteoblast differentiation, and gene expression are altered in human osteoblasts from hypertrophic fracture non-unions. Bone 2008, 42:894-906.
23. Schindeler A., Little D.G. Recent insights into bone development, homeostasis, and repair in type 1 neurofibromatosis (NF1). Bone 2008, 42:616-622.
24. Kuorilehto T., Nissinen M., Koivunen J., Benson M.D., Peltonen J. NF1 tumor suppressor protein and mRNA in skeletal tissues of developing and adult normal mouse and NF1-deficient embryos. J Bone Miner Res 2004, 19:983-9.
25. Kolanczyk M., Kossler N., Kühnisch J., Lavitas L., Stricker S., Wilkening U., et al. Multiple roles for neurofibromin in skeletal development and growth. Hum Mol Genet 2007, 16:874-886.
26. Stevenson D.A., Zhou H., Ashrafi S., Messiaen L.M., Carey J.C., D'Astous J.L., et al. Double inactivation of NF1 in tibial pseudarthrosis. Am J Hum Genet 2006, 79:143-148.
27. Mornet E. Hypophosphatasia. Best Pract Res Clin Rheumatol 2008, 22:113-127.
28. Stein G.S., Lian J.B., van Wijnen A.J., Stein J.L., Montecino M., Javed A., et al. Runx2 control of organization, assembly and activity of the regulatory machinery for skeletal gene expression. Oncogene 2004, 3:4315-4329.
29. Huang W., Yang S., Shao J., Li Y.P. Signaling and transcriptional regulation in osteoblast commitment and differentiation. Front Biosci 2007, 2:3068-3092.
30. Yu X., Chen S., Potter O.L., Murthy S.M., Li J., Pulcini J.M., et al. Neurofibromin and its inactivation of Ras are prerequisites for osteoblast functioning. Bone 2005, 793-802.
31. Xiao G., Jiang D., Thomas P., Benson M.D., Guan K., Karsenty G., et al. MAPK pathways activate and phosphorylate the osteoblast-specific transcription factor, Cbfa 1. J Biol Chem 2000, 275:4453-4459.
32. Abdel-Wanis M.E., Kawahara N. Bone development in neurofibromatosis 1. Med Hypotheses 2003, 60:459-462.
33. Ogata Y. Bone sialoprotein and its transcriptional regulatory mechanism. J Periodontal Res 2008, 43:127-135.
34. Motamed K. SPARC (osteonectin/BM-40). Int J Biochem Cell Biol 1999, 31:1363-1366.